Tumor treating induced fields: a new treatment option for patients with glioblastoma

Zehao Cai, Zhe Yang, Ying Wang, Ye Li, Hong Zhao, Hanwen Zhao, Xue Yang, Can Wang, T T Meng, Tong Xiao, Hao Zheng, Zhongyuan He, C. Niu, Jinfang Yang, Feng Chen, Yang Zhi, Zhiqiang Zou, Wenbin LiFrontiers in Neurology 2024 · DOI

Abstract

Tumor Treating Induced Fields (TTIF) significantly inhibited the proliferation of U87 cells both in vitro and in vivo. Consequently, TTIF emerges as a potential treatment option for patients with progressive or metastatic glioblastoma (GBM).

Introduction: The Challenge of Glioblastoma

Glioblastoma (GBM) is a highly aggressive brain tumor with a notoriously poor prognosis. While standard treatments include surgery, radiation, and chemotherapy, a newer modality called Tumor Treating Fields (TTFields) has shown clinical success. TTFields work by applying intermediate-frequency alternating electric fields to disrupt cancer cell division.

However, existing TTFields devices have severe physical limitations. They require patients to shave their heads and wear capacitor-like, insulated electrodes glued directly to the scalp. This is not only cumbersome and expensive due to disposable parts, but also anatomically restrictive. It is difficult to arrange opposing electrode arrays to effectively treat tumors in the lower brain (infratentorial) or the spinal cord. The authors tackle this gap by developing a device that generates therapeutic electric fields via electromagnetic induction rather than direct electrical contact.

The TTIF Approach: Induction Over Contact

The researchers designed a TTIF device consisting of a motor, an LC resonance circuit, and a magnetic ring. The circuit converts low-voltage direct current into high-voltage, medium-frequency (200 kHz) alternating current within an inductor coil. This generates an alternating magnetic field in the ring, which in turn induces an alternating electric field in the target tissue placed within or near it.

The prototype TTIF device featuring a magnetic ring and induction coil.

The core innovation is the shift from capacitive coupling (electrodes on the skin) to inductive coupling. This effectively turns the tumor microenvironment into the secondary coil of a transformer, inducing micro-alternating currents directly inside the tissue without requiring skin-contact electrodes.

Mechanisms and Field Distribution

To validate the approach, the team used Finite Element Analysis (FEA) to model the electric field distribution generated by the magnetic ring on human head models. These simulations revealed a radial, "geyser-like" or fountain-like distribution of electric field lines.

FEA simulation showing the radial, 'geyser-like' electric field distribution generated by the magnetic ring.

This proves that a single, non-contact ring can achieve the necessary voltage and current density (>1,000 mA/m²) to reach brain tissue, bypassing the need for opposing electrode pairs. Biologically, exposure to TTIF doesn't just slow growth; it physically stresses the cells. In vitro observations showed an increase in circular cells and the emergence of cytoplasmic vacuoles, classic signs of disrupted cellular proliferation and impending cell death.

Key Experimental Results

The efficacy of the TTIF system was demonstrated across several models:

  • In Vitro: After 72 hours of TTIF exposure at 200 kHz, U87 glioblastoma cell density was markedly decreased compared to controls.
  • Subcutaneous Tumors: After 21 days of continuous treatment in mice, tumor volumes were significantly suppressed ($p=0.007$), with a corresponding drop in tumor weight ($p=0.010$). Organ weights remained unaffected, indicating systemic safety.
  • Intracranial Tumors: In in situ brain tumor models, TTIF successfully prolonged the median overall survival (OS) of the mice to 47 days, compared to 37 days for the untreated control group ($p=0.0274$).

Limitations and Future Work

The authors acknowledge that because of the LC resonance circuit's design, the frequency and current density vary together, making it difficult to isolate the exact independent thresholds required to kill cells. Additionally, while the team designed a smaller, wearable magnetic ring (4 cm diameter) intended for human use, they have yet to miniaturize it sufficiently for use on awake, moving mice. Future work will focus on miniaturizing the device for animal testing and elucidating the exact molecular mechanisms of action.

Summary updated

Abstract

TTIF significantly inhibited the proliferation of U87 cells both <i>in vitro</i> and <i>in vivo</i>. Consequently, TTIF emerges as a potential treatment option for patients with progressive or metastatic GBM.
BibTeX
@inproceedings{cai2024tumor,
  author = {Zehao Cai and Zhe Yang and Ying Wang and Ye Li and Hong Zhao and Hanwen Zhao and Xue Yang and Can Wang and T T Meng and Tong Xiao and Hao Zheng and Zhongyuan He and C. Niu and Jinfang Yang and Feng Chen and Yang Zhi and Zhiqiang Zou and Wenbin Li},
  title = {{Tumor treating induced fields: a new treatment option for patients with glioblastoma}},
  booktitle = {Frontiers in Neurology},
  year = {2024},
  doi = {10.3389/fneur.2024.1413236},
}
Figure